Documented formulation project · 02
FolliGenz Aminexil 2% + Encapsulated Retinol + MCT C6/C8 Low-Ethanol Scalp Serum
How Biotica Consulting translated a multi-pathway scalp-care hypothesis into a pilot-evaluation research, formulation, testing, and packaging brief for FolliGenz and its China-side development work with Hemu Haohai.
- Organizations
- FolliGenz Therapeutics Corporation × Nanjing Hemu Haohai Biotechnology Co., Ltd.
- Project period
- Documentation dated May–July 2026
- Prepared by
- Biotica Consulting LLC
- Last reviewed
- July 31, 2026
- Status
- Prototype, quality documentation, and listing support
- Format
- Cross-border formulation development
This is a documented project case study. Biotica Consulting LLC provided scientific research and formulation-development support for FolliGenz Therapeutics Corporation. Hemu Haohai served as the China-side manufacturing interface and coordinated samples. Later quality and listing records supplied with the project use the generic name Scalp Serum and the listed name FluxArco ANTI-HAIR LOSS ESSENCE LIQUID, so the page preserves those distinctions rather than treating the records as an independently proven one-to-one identity match. Private correspondence, commercial terms, the complete confidential manufacturing formula, the facility FEI, and the product-listing number are not published.
The development question and the work behind it
FolliGenz wanted a daily leave-on scalp serum that did more than place a single active in a conventional high-alcohol vehicle. Biotica Consulting evaluated a complementary design built around 2% Diaminopyrimidine Oxide, commonly marketed as Aminexil, a C6/C8 medium-chain triglyceride phase, encapsulated retinol, and a broad hydration and comfort system in a low-ethanol vehicle.
Biotica converted that concept into an OEM implementation package covering phase architecture, a scaled manufacturing sequence, process guardrails, pilot-release criteria, protective packaging, stability and microbiology expectations, and careful claim boundaries. FolliGenz directed product and commercialization decisions, while Hemu Haohai served as the China-side interface for factory feasibility, prototype handling, documentation questions, and sample logistics. Later supplied records document batch-quality checks and a MoCRA-related facility and product listing handoff. According to the project team, stability testing supported a reported 24-month product life. The underlying protocol and report were not supplied for this public update, so that result is presented as project-reported and is not inferred from the COA or registration document.
Defined roles across the project
Biotica Consulting LLC
Reviewed the mechanistic literature, separated plausible formulation rationale from unproven claims, designed the formula architecture, and prepared the OEM handoff process, specification, packaging, and validation brief.
FolliGenz Therapeutics Corporation
Defined the product direction and constraints, reviewed development decisions, and coordinated quality, stability, packaging, scale, and commercialization questions with manufacturing partners.
Nanjing Hemu Haohai Biotechnology Co., Ltd.
Relayed factory feasibility, arranged prototype and sample work, and supported documentation, packaging, and logistics discussions during the development handoff.
A traceable development path
- 01
Related listing documentation recorded
A supplied third-party registration-agent record identifies a MoCRA-related facility and cosmetic product listing for FluxArco ANTI-HAIR LOSS ESSENCE LIQUID at Guangzhou Huaxia Biopharmaceuticals. It is a listing record, not FDA approval, and its product name is not identical to the internal formulation-development title.
- 02
Production brief issued
Biotica documented the target composition, manufacturing sequence, process controls, packaging requirements, and release and stability expectations in a pilot-evaluation technical brief.
- 03
Factory feasibility, samples, and batch documentation
FolliGenz and Hemu Haohai exchanged manufacturing, sample, package, documentation, shelf-life, and scale questions. A supplied semi-finished scalp-serum COA dated July 2026 records batch-quality observations, pH, short physical-stress checks, and microbial counts.
- 04
24-month stability outcome reported
The supplied project photo records pilot samples, and the project team reports that stability testing supported a 24-month product life. The underlying report was not included in the materials reviewed for this public update, and the short COA checks shown below are not a substitute for it.
From formulation brief to documented product controls
The supplied project record extends from formulation research into batch-quality documentation and a regulatory-listing handoff. Selected pages are reproduced below as WebP images so the public case study can show the evidence without posting the source PDFs, protected listing identifiers, or private contact details.
According to the project team, stability testing supported a reported 24-month product life. The underlying 24-month protocol and report were not among the records reviewed for this update. The separate COA shown here documents July 2026 batch QC and short physical-stress checks; it does not by itself establish the two-year outcome.
The supplied registration-agent page concerns FluxArco ANTI-HAIR LOSS ESSENCE LIQUID and Guangzhou Huaxia Biopharmaceuticals. It is third-party documentation associated with a MoCRA facility-registration and product-listing handoff. The document itself states that it does not represent FDA endorsement, and FDA explains that cosmetic registration and listing are not an approval program.
Related FDA Cosmetics Direct screenshots supplied with the project show the submission as Submission Accepted and the product as Listed with an effective date of May 26, 2026. Those portal statuses record completion of the listing submission workflow. They do not show FDA review or approval of safety, efficacy, claims, formula, or shelf life, and the unredacted portal screenshots are not reproduced publicly.
Agent-issued MoCRA registration and listing record
This record was issued by Shenzhen CDT Testing, not by FDA. It names Guangzhou Huaxia Biopharmaceuticals and FluxArco ANTI-HAIR LOSS ESSENCE LIQUID and disclaims FDA endorsement. The public copy withholds the facility FEI, product-listing number, street address, agent identity and signature, contact details, and private certificate dates. FDA does not issue certificates for cosmetic facility registrations or product listings.
Identity, organoleptic checks, and pH
The supplied COA identifies a July 2026 semi-finished scalp-serum batch and records consistent color, odor, and appearance with a measured pH of 5.5 at 25 °C. The customer field is unfilled and the product name is generic, so product-level traceability still requires reconciliation.
Physical stability and microbial observations
The COA records Normal results after 24 hours at 40 ± 1 °C, after 24 hours at −8 ± 2 °C, and after a separate 30-minute centrifugation check at 2,000 r/min. Total aerobic microbial count and total yeast and mold count were each reported below 10 CFU/g. These are batch-level checks, not the underlying 24-month stability dataset.
Traceability note: the internal development title, the COA name Scalp Serum, and the listed name FluxArco ANTI-HAIR LOSS ESSENCE LIQUID are different. They are shown as records supplied in the project context, not as an independently verified identity bridge. The supplied COA copy also has blank inspector and approval-signatory lines, and no issuing organization is named. A release file should reconcile the formula version, batch, facility, package, product name, signed quality authorization, and listing record.
Questions the work was designed to answer
- How can a highly water-compatible Aminexil phase and a lipid-dependent retinol system coexist in a stable, low-ethanol leave-on emulsion?
- Can the lipid phase prioritize light feel and retinol delivery while avoiding overstatement of an antifungal effect?
- Which hydration and soothing components make repeated use more practical without relying on propylene glycol, fragrance, menthol, or a high alcohol load?
- What process controls, package choices, and release tests should an OEM receive before scale-up?
What the project record supports
Aminexil was framed as a collagen-maturation hypothesis
Biotica traced Aminexil to 2,4-diaminopyrimidine 3-oxide and the foundational in-vitro work on lysyl-hydroxylase expression. The rationale is to support a more flexible perifollicular environment, not to claim that the serum reverses fibrosis, acts as minoxidil, or regrows hair.
The vehicle was designed as part of the product strategy
The formula combines a dissolved aqueous active with a protected C6/C8 lipid phase and encapsulated retinol in a light, low-ethanol milky emulsion. The complete composition, supplier specifications, and processing parameters remain confidential.
MCT is a carrier first and a microbiome-conscious hypothesis second
C6/C8 MCT carries the retinol phase, improves spread, and avoids heavier long-chain oils. Laboratory literature provides a reason to test a secondary yeast-environment hypothesis, but species, concentration, free-fatty-acid content, topical conditions, and finished-formula behavior matter. The finished emulsion is not presented as an antifungal treatment.
Encapsulation supports controlled handling, not automatic efficacy
Encapsulated retinol was selected to reduce direct exposure and improve handling of a light- and oxygen-sensitive material. Cool-down addition, limited post-addition shear, antioxidant and chelator support, and opaque airless packaging were built into the transfer plan. Retinol retention, carrier integrity, and active-content verification still require suitable supplier and finished-product data.
Tolerability was treated as a development requirement
A broad humectant and comfort system, low ethanol, and exclusions for propylene glycol, polypropylene glycol, fragrance, essential oils, and menthol were chosen to make routine use more plausible. These choices do not replace finished-product irritation or use testing.
The handoff defined what must be proven next
Biotica specified pilot-release targets, protective packaging, microbial and preservative testing, accelerated and real-time stability, and active verification. The project team later reported stability testing supporting a 24-month product life, but the underlying protocol and report were not supplied for this public update. Separate comparative studies would still be needed to establish any Aminexil–MCT additive effect or Malassezia-related claim.
The supplied COA documents batch checks, not two years of stability
The July 2026 semi-finished scalp-serum COA records pH 5.5, passing organoleptic observations, Normal results after the specified 24-hour hot and cold holds, a separate 30-minute centrifugation check at 2,000 r/min, and total aerobic plus yeast and mold counts each below 10 CFU/g. Those results support a dated batch-quality record. They do not replace the underlying protocol, timepoints, assays, acceptance criteria, package conditions, and final report needed to substantiate the reported 24-month product life.
A cosmetic listing record is not FDA approval
The supplied third-party registration-agent record is associated with a MoCRA facility-registration and product-listing handoff for a differently named product at Guangzhou Huaxia Biopharmaceuticals. FDA states that cosmetic product facility registration and product listing are not an approval program and that FDA does not issue certificates for cosmetic product facility registrations or product listings. The record does not establish FDA review of the formula, safety, efficacy, claims, stability, or the identity link to this internal development title.
What must be proven before stronger claims
The project record is a development input, not permission to outrun the evidence. These are the next questions for direct testing and review.
- Can the complete 24-month stability protocol and signed report be matched to the exact formula version, batch, package, storage conditions, timepoints, methods, assays, acceptance criteria, and conclusion?
- Does Aminexil remain fully dissolved through real-time, accelerated, freeze-thaw, and package-compatibility studies?
- Does the encapsulated-retinol system retain active content and delivery integrity throughout the intended shelf life?
- Does the preserved finished emulsion pass microbial limits and a suitable preservative challenge test?
- Do the selected airless components protect the product and dispense the intended dose consistently?
- Does repeat-use tolerability support the proposed directions in the target population?
- Can any microbiome or Malassezia language be supported by a finished-product study against relevant species and a matched vehicle?
- Have cosmetic, medical, trademark, and market-specific claims been reviewed for each intended jurisdiction?
Progress stated at the level the work supports
Biotica's contribution was the disciplined bridge between an interesting biological concept and a buildable development package. The record now includes pilot samples, a client-reported 24-month stability outcome, selected batch-quality checks, and a related regulatory-listing handoff. Those records support development progress, not a claim of FDA approval or demonstrated clinical hair-growth or antifungal efficacy.
Hemu Haohai connected ingredient sourcing to an executable OEM path
FolliGenz and Biotica worked with Nanjing Hemu Haohai Biotechnology as the China-side formulation, API supply, and OEM coordination partner for this program.
The collaboration connected active and excipient research with factory feasibility, prototype preparation, packaging, quality documentation, stability planning, and international logistics. It is a practical example of how API supply intelligence moves from source research into a finished-product development path.
Project records and public sources
Selected pages from supplied private records are reproduced as public-safe WebP images with the facility FEI, product-listing number, street address, and private agent details withheld. The full PDFs, correspondence, and confidential formula are not posted; the underlying 24-month stability protocol and report were not supplied for this public update. Public literature informed the development rationale; none of the cited papers tests this exact finished formula.
- 01Private project record
Final Production Formula v1.0
FolliGenz project record · Confidential manufacturing brief
- 02Private project record
FolliGenz–Hemu Haohai development correspondence
Supplied project record · Private correspondence · July 2026
- 03Private project record
24-month stability outcome update
FolliGenz project record · Client-provided project update
- 04Selected pages shown above
Certificate of Analysis: Semi-Finished Scalp Serum, HX-RE-QA-026
Supplied project quality record · Batch QC copy · July 2026
- 05Redacted first page shown above
Third-party cosmetic facility and product-listing record
Shenzhen CDT Testing Technology Co., Ltd. · Registration-agent record · May 2026
- 06Private project record
Cosmetics Direct submission and product-listing screenshots
Supplied project documentation · Portal records · May 26, 2026
- 07View source
Registration and Listing of Cosmetic Product Facilities and Products
U.S. Food and Drug Administration · Official FDA guidance
- 08View source
Does FDA approve cosmetics before they go on the market?
U.S. Food and Drug Administration · Official FDA explainer
- 09View source
FolliGenz Therapeutics: About Us
FolliGenz Therapeutics Corporation · Official company page
- 10View source
Nanjing Hemu Haohai Biotechnology
Nanjing Hemu Haohai Biotechnology Co., Ltd. · Official company site
- 11View source
A minoxidil-related compound lacking a C6 substitution still inhibits lysyl hydroxylase gene expression in vitro
PubMed · Peer-reviewed mechanistic study
- 12View source
Perifollicular fibrosis: pathogenetic role in androgenetic alopecia
PubMed · Peer-reviewed human tissue study
- 13View source
Medium-chain triglycerides inhibit growth of Malassezia
PubMed · Peer-reviewed in-vitro study
- 14View source
Analysis of Malassezia lipidome disclosed differences among species and strains
Frontiers in Cellular and Infection Microbiology · Peer-reviewed lipidomics study
- 15View source
The effect of medium-chain triglycerides oil on Candida albicans
PubMed · Peer-reviewed experimental study
- 16View source
Encapsulation and controlled release of retinol from silicone particles for topical delivery
PubMed · Peer-reviewed delivery study
Project evidence and literature must be read within their stated methods and limitations. This page is not medical, clinical, regulatory, or legal advice.
Related projects and research
Follow adjacent formulation, partner, supplier, and research questions while keeping each evidence type clearly labeled.
Need a development question turned into a testable brief?
Biotica can connect literature review, formulation strategy, partner coordination, market analysis, and a validation roadmap around the decision your team needs to make.
Discuss a development project